

General information about company	
Scrip code	531633
NSE Symbol	LINCOLN
MSEI Symbol	NOTLISTED
ISIN	INE405C01035
Name of the entity	LINCOLN PHARMACEUTICALS LTD
Date of start of financial year	01-04-2021
Date of end of financial year	31-03-2022
Reporting Quarter	Yearly
Date of Report	31-03-2022
Risk management committee	Applicable
Market Capitalisation as per immediate previous Financial Year	Top 2000 listed entities

Annexure I

Annexure I to be submitted by listed entity on quarterly basis

I. Composition of Board of Directors

Disclosure of notes on composition of board of directors explanatory

Whether the listed entity has a Regular Chairperson

Yes

Whether Chairperson is related to MD or CEO

No

PAN	DIN	Category 1 of directors	Category 2 of directors	Category 3 of directors	Date of Birth	Whether special resolution passed? [Refer Reg. 17(1A) of Listing Regulations]	Date of passing special resolution	Initial Date of appointment	Date of Re-appointment	Date of cessation	Tenure of director (in months)	No of Directorship in listed entities including this listed entity (Refer Regulation 17A of Listing Regulations)	No of Independent Directorship in listed entities including this listed entity (Refer Regulation 17A(1) of Listing Regulations)	Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations)	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)
BLXPS9450B	02769085	Non-Executive - Non Independent Director	Chairperson		04-03-1944	Yes	29-09-2018	16-08-1995	18-07-1996			1	0	0	0
ABIPP9463H	00104706	Executive Director	Not Applicable	MD	26-01-1954	NA		20-01-1995	01-10-2019			1	0	1	0
ABOPP5912D	00104834	Executive Director	Not Applicable		08-12-1958	NA		20-01-1995	01-10-2019			1	0	1	0
AFXPP7705F	02319308	Executive Director	Not Applicable		26-06-1982	NA		14-11-2014	14-11-2019			2	0	1	0

I. Composition of Board of Directors

Disclosure of notes on composition of board of directors explanatory

Whether the listed entity has a Regular Chairperson

Sr	Title (Mr / Ms)	Name of the Director	PAN	DIN	Category 1 of directors	Category 2 of directors	Category 3 of directors	Date of Birth	Whether special resolution passed? [Refer Reg. 17(1A) of Listing Regulations]	Date of passing special resolution	Initial Date of appointment	Date of Re-appointment	Date of cessation	Tenure of director (in months)	No of Directorship in listed entities including this listed entity (Refer Regulation 17A of Listing Regulations)	No of Independent Directorship in listed entities including this listed entity (Refer Regulation 17A(1) of Listing Regulations)	Nur mem in . Stak Com inclu liste (F Reg 26 Li Regt
5	Mr	Ashish Rajmibhai Patel	AGAPP6089Q	01309017	Executive Director	Not Applicable		12-05-1981	NA		14-11-2014	14-11-2019			1	0	0
6	Mr	Rajnikant Gulabdas Patel	ABIPP9440Q	00104786	Non-Executive - Non Independent Director	Not Applicable		05-02-1958	NA		20-01-1995	08-06-2018			1	0	0
7	Mr	Arvind Gulabdas Patel	AGWPP5494P	00104885	Non-Executive - Non Independent Director	Not Applicable		29-09-1950	NA		03-02-1995	14-11-2014			1	0	0
8	Mr	Ishwarlal Ambalal Patel	ABRPP7054R	00217324	Non-Executive - Independent Director	Not Applicable		15-01-1933	Yes	29-09-2018	03-02-1995	01-04-2019		96	1	1	2

I. Composition of Board of Directors

Disclosure of notes on composition of board of directors explanatory

Whether the listed entity has a Regular Chairperson

Sr	Title (Mr / Ms)	Name of the Director	PAN	DIN	Category 1 of directors	Category 2 of directors	Category 3 of directors	Date of Birth	Whether special resolution passed? [Refer Reg. 17(1A) of Listing Regulations]	Date of passing special resolution	Initial Date of appointment	Date of Re-appointment	Date of cessation	Tenure of director (in months)	No of Directorship in listed entities including this listed entity (Refer Regulation 17A of Listing Regulations)	No of Independent Directorship in listed entities including this listed entity (Refer Regulation 17A(1) of Listing Regulations)	Number in Statutory Corporate Body (Refer Regulation 17A(1) of Listing Regulations)
9	Mr	Pirabhai Ramjibhai Suthar	AMJPS5860M	00453047	Non-Executive - Independent Director	Not Applicable		07-05-1946	Yes	30-09-2020	30-10-1999	01-04-2019		96	1	1	1
10	Ms	Meha Mahesh Patel	CHSPP9571Q	07254852	Non-Executive - Independent Director	Not Applicable		28-06-1990	NA		04-08-2015	04-08-2020		80	1	1	0
11	Mr	Saurin Jagdish Parikh	ABRPP8740J	02136530	Non-Executive - Independent Director	Not Applicable		28-09-1971	NA		27-03-2018	29-09-2018		48	2	1	1

Audit Committee Details							
Whether the Audit Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	00217324	Ishwarlal Ambalal Patel	Non-Executive - Independent Director	Chairperson	20-02-2001		
2	00453047	Pirabhai Ramjibhai Suthar	Non-Executive - Independent Director	Member	20-02-2001		
3	02319308	Munjal Mahendra Patel	Executive Director	Member	30-05-2019		

Nomination and remuneration committee							
Whether the Nomination and remuneration committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	00217324	Ishwarlal Ambalal Patel	Non-Executive - Independent Director	Chairperson	30-10-2002		
2	00453047	Pirabhai Ramjibhai Suthar	Non-Executive - Independent Director	Member	30-10-2002		
3	07254852	Meha Mahesh Patel	Non-Executive - Independent Director	Member	30-05-2019		

Stakeholders Relationship Committee							
Whether the Stakeholders Relationship Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	00217324	Ishwarlal Ambalal Patel	Non-Executive - Independent Director	Chairperson	31-01-2002		
2	00104706	Mahendra Gulabdas Patel	Executive Director	Member	31-01-2002		
3	00104834	Hashmukh Ishwarlal Patel	Executive Director	Member	31-01-2002		

Risk Management Committee							
Whether the Risk Management Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	00217324	Ishwarlal Ambalal Patel	Non-Executive - Independent Director	Chairperson	25-05-2021		
2	02319308	Munjal Mahendra Patel	Executive Director	Member	25-05-2021		
3	99999999	Darshit Ashvinkumar Shah	Member	Member	25-05-2021		

Corporate Social Responsibility Committee							
Whether the Corporate Social Responsibility Committee has a Regular Chairperson					No		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	00217324	Ishwarlal Ambalal Patel	Non-Executive - Independent Director	Member	24-04-2014		
2	00104706	Mahendra Gulabdas Patel	Executive Director	Member	24-04-2014		
3	02319308	Munjal Mahendra Patel	Executive Director	Member	30-05-2019		

Other Committee						
Sr	DIN Number	Name of Committee members	Name of other committee	Category 1 of directors	Category 2 of directors	Remarks

Annexure 1							
Annexure 1							
III. Meeting of Board of Directors							
Disclosure of notes on meeting of board of directors explanatory							
Sr	Date(s) of meeting (if any) in the previous quarter	Date(s) of meeting (if any) in the current quarter	Maximum gap between any two consecutive (in number of days)	Notes for not providing Date	Whether requirement of Quorum met (Yes/No)	Number of Directors present* (All directors including Independent Director)	No. of Independent Directors attending the meeting*
1	05-10-2021			Due to oversight, the details of date of board meeting for the purpose of allotment of equity shares, pursuant to scheme of amalgamation held on October 05, 2021 was not mention in previous quarterly report of corporate governance, however, this is inadvertent error only. Further, Company have made relevant disclosure w.r.t intimation of board meeting for intimation of allotment of equity shares and also necessary intimation as specified under SEBI (LODR) Regulations, 2015 from time to time.	Yes	7	4
2	11-11-2021		36		Yes	6	3
3		10-02-2022	90		Yes	7	3

Annexure 1								
IV. Meeting of Committees								
Disclosure of notes on meeting of committees explanatory								
Sr	Name of Committee	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Maximum gap between any two consecutive (in number of days)	Name of other committee	Reason for not providing date	Whether requirement of Quorum met (Yes/No)	Number of Directors present* (All directors including Independent Director)	No. of Independent Directors attending the meeting*
1	Audit Committee	11-11-2021				Yes	3	2
2	Audit Committee	10-02-2022	90			Yes	3	2
3	Stakeholders Relationship Committee	11-10-2021				Yes	3	1
4	Stakeholders Relationship Committee	08-12-2021				Yes	3	1
5	Stakeholders Relationship Committee	14-03-2022				Yes	3	1
6	Stakeholders Relationship Committee	23-03-2022				Yes	3	1

Annexure 1								
IV. Meeting of Committees								
Sr	Name of Committee	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Maximum gap between any two consecutive (in number of days)	Name of other committee	Reason for not providing date	Whether requirement of Quorum met (Yes/No)	Number of Directors present* (All directors including Independent Director)	No. of Independent Directors attending the meeting*
7	Corporate Social Responsibility Committee	11-11-2021				Yes	3	1
8	Risk Management Committee	11-11-2021				Yes	3	1

Annexure 1			
V. Related Party Transactions			
Sr	Subject	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
1	Whether prior approval of audit committee obtained	Yes	
2	Whether shareholder approval obtained for material RPT	Yes	
3	Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit Committee	NA	

Annexure 1		
VI. Affirmations		
Sr	Subject	Compliance status (Yes/No)
1	The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015	Yes
2	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015 a. Audit Committee	Yes
3	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. b. Nomination & remuneration committee	Yes
4	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. c. Stakeholders relationship committee	Yes
5	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. d. Risk management committee (applicable to the top 500 listed entities)	Yes
6	The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
7	The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
8	This report and/or the report submitted in the previous quarter has been placed before Board of Directors.	Yes

Annexure 1		
Sr	Subject	Compliance status
1	Name of signatory	MAHENDRA G. PATEL
2	Designation	Managing Director

Annexure II				
Annexure II to be submitted by listed entity at the end of the financial year (for the whole of financial year)				
I. Disclosure on website in terms of Listing Regulations				
Sr	Item	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.	Web address
1	Details of business	Yes		https://www.lincolnpharma.com/about-us/
2	Terms and conditions of appointment of independent directors	Yes		http://investors.lincolnpharma.com/uploads/2014/11/Terms-and-Conditions-of-Appointment-letter-of-Independent-Director.pdf
3	Composition of various committees of board of directors	Yes		http://investors.lincolnpharma.com/uploads/2019/08/Composition-of-the-Committees.pdf
4	Code of conduct of board of directors and senior management personnel	Yes		http://investors.lincolnpharma.com/uploads/2014/11/Code-of-Conduct.pdf
5	Details of establishment of vigil mechanism/ Whistle Blower policy	Yes		http://investors.lincolnpharma.com/uploads/2014/11/Vigil-Mechanism-Whistle-Blower-Policy.pdf
6	Criteria of making payments to non-executive directors	NA		
7	Policy on dealing with related party transactions	Yes		http://investors.lincolnpharma.com/uploads/2014/11/Policy-on-Related-Party-Transactions.pdf
8	Policy for determining 'material' subsidiaries	NA		
9	Details of familiarization programmes imparted to independent directors	Yes		http://investors.lincolnpharma.com/uploads/2014/11/Policy-on-Familiarisation-Programme-of-Independent-Directors.pdf

Annexure II				
Annexure II to be submitted by listed entity at the end of the financial year (for the whole of financial year)				
I. Disclosure on website in terms of Listing Regulations				
Sr	Item	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.	Web address
10	Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances	Yes		http://investors.lincolnpharma.com/uploads/2020/03/Investor-Information.pdf
11	email address for grievance redressal and other relevant details	Yes		http://investors.lincolnpharma.com/uploads/2020/03/Investor-Information.pdf
12	Financial results	Yes		https://www.lincolnpharma.com/lpinvestors/
13	Shareholding pattern	Yes		https://www.lincolnpharma.com/lpinvestors/
14	Details of agreements entered into with the media companies and/or their associates	NA		
15	Schedule of analyst or institutional investor meet and presentations made by the listed entity to analysts or institutional investors simultaneously with submission to stock exchange	NA		
16	New name and the old name of the listed entity	NA		
17	Advertisements as per regulation 47 (1)	Yes		https://www.lincolnpharma.com/lpinvestors/
18	Credit rating or revision in credit rating obtained	Yes		https://www.lincolnpharma.com/lpinvestors/
19	Separate audited financial statements of each subsidiary of the listed entity in respect of a relevant financial year	Yes		https://www.lincolnpharma.com/lpinvestors/
20	Whether company has provided information under separate section on its website as per	Yes		https://www.lincolnpharma.com/lpinvestors/

	Regulation 46(2)			
21	Materiality Policy as per Regulation 30	Yes		http://investors.lincolnpharma.com/uploads/2014/11/Policy-on-Disclosure-of-Material-Event.pdf
22	Dividend Distribution policy as per Regulation 43A (as applicable)	Yes		https://www.lincolnpharma.com/investors/uploads/2022/04/Dividend%20Distribution%20Policy.pdf?t=1649318313
23	It is certified that these contents on the website of the listed entity are correct	Yes		http://www.lincolnpharma.com/about-us/investors/

Annexure II				
II. Annual Affirmations				
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
1	Independent director(s) have been appointed in terms of specified criteria of 'independence' and/or 'eligibility'	16(1)(b) & 25(6)	Yes	
2	Board composition	17(1), 17(1A) & 17(1B)	Yes	
3	Meeting of Board of directors	17(2)	Yes	
4	Quorum of Board meeting	17(2A)	Yes	
5	Review of Compliance Reports	17(3)	Yes	
6	Plans for orderly succession for appointments	17(4)	Yes	
7	Code of Conduct	17(5)	Yes	
8	Fees/compensation	17(6)	Yes	
9	Minimum Information	17(7)	Yes	
10	Compliance Certificate	17(8)	Yes	

Annexure II				
II. Annual Affirmations				
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
11	Risk Assessment & Management	17(9)	Yes	
12	Performance Evaluation of Independent Directors	17(10)	Yes	
13	Recommendation of Board	17(11)	Yes	
14	Maximum number of Directorships	17A	Yes	
15	Composition of Audit Committee	18(1)	Yes	
16	Meeting of Audit Committee	18(2)	Yes	
17	Composition of nomination & remuneration committee	19(1) & (2)	Yes	
18	Quorum of Nomination and Remuneration Committee meeting	19(2A)	Yes	
19	Meeting of Nomination and Remuneration Committee	19(3A)	Yes	
20	Composition of Stakeholder Relationship Committee	20(1), 20(2) & 20(2A)	Yes	

Annexure II				
II. Annual Affirmations				
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
21	Meeting of Stakeholders Relationship Committee	20(3A)	Yes	
22	Composition and role of risk management committee	21(1),(2),(3),(4)	Yes	
23	Meeting of Risk Management Committee	21(3A)	Yes	
24	Vigil Mechanism	22	Yes	
25	Policy for related party Transaction	23(1),(1A),(5), (6),(7) & (8)	Yes	
26	Prior or Omnibus approval of Audit Committee for all related party transactions	23(2), (3)	Yes	
27	Approval for material related party transactions	23(4)	Yes	
28	Disclosure of related party transactions on consolidated basis	23(9)	Yes	
29	Composition of Board of Directors of unlisted material Subsidiary	24(1)	NA	
30	Other Corporate Governance requirements with respect to subsidiary of listed entity	24(2),(3),(4),(5) & (6)	Yes	

Annexure II				
II. Annual Affirmations				
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
31	Annual Secretarial Compliance Report	24(A)	Yes	
32	Alternate Director to Independent Director	25(1)	Yes	
33	Maximum Tenure	25(2)	Yes	
34	Meeting of independent directors	25(3) & (4)	Yes	
35	Familiarization of independent directors	25(7)	Yes	
36	Declaration from Independent Director	25(8) & (9)	Yes	
37	D & O Insurance for Independent Directors	25(10)	Yes	
38	Memberships in Committees	26(1)	Yes	
39	Affirmation with compliance to code of conduct from members of Board of Directors and Senior management personnel	26(3)	Yes	
40	Disclosure of Shareholding by Non-Executive Directors	26(4)	Yes	
41	Policy with respect to Obligations of directors and senior management	26(2) & 26(5)	Yes	
	Any other information to be provided - Add Notes			

Annexure II		
1	Name of signatory	MAHENDRA G. PATEL
2	Designation	Managing Director

Annexure II		
III. Affirmations		
Sr	Particulars	Compliance status (Yes/No/NA)
1	The Listed Entity has approved Material Subsidiary Policy and the Corporate Governance requirements with respect to subsidiary of Listed Entity have been complied	NA
	Any other information to be provided	

Annexure II		
1	Name of signatory	MAHENDRA G. PATEL
2	Designation	Managing Director

Additional Half yearly Disclosure			
Applicability of disclosure	Applicable		
Reason for Non Applicability	Textual Information(1)		
I. Disclosure of Loans/ guarantees/comfort letters /securities etc.refer note below			
(A)Any loan or any other form of debt advanced by the listed entity directly or indirectly to			
Entity	Aggregate amount advanced during six months	Balance outstanding at the end of six months	
Promoter or any other entity controlled by them	0	0	
Promoter Group or any other entity controlled by them	2500000	0	
Directors (including relatives) or any other entity controlled by them	0	0	
KMPs or any other entity controlled by them	0	0	
(B) Any guarantee / comfort letter (by whatever name called) provided by the listed entity directly or indirectly, in connection with any loan(s) or any other form of debt availed By			
Entity	Type (guarantee, comfort letter etc.)	Aggregate amount of issuance during six months	Balance outstanding at the end of six months(taking into account any invocation)
Promoter or any other entity controlled by them	0	0	0
Promoter Group or any other entity controlled by them	0	0	0
Directors (including relatives) or any other entity controlled by them	0	0	0
KMPs or any other entity controlled by them	0	0	0
(C) Any security provided by the listed entity directly or indirectly, in connection with any loan(s) or any other form of debt availed by			
Entity	Type of security (cash, shares etc.)	Aggregate value of security provided during six months	Balance outstanding at the end of six months
Promoter or any other entity controlled by them	0	0	0
Promoter Group or any other entity controlled by them	0	0	0
Directors (including relatives) or any other entity controlled by them	0	0	0
KMPs or any other entity controlled by them	0	0	0
(D) Additional Information			Textual Information(2)
II. Affirmations			
Affirmations		Compliance Status	Company Remarks
All loans (or other form of debt), guarantees, comfort letters (by whatever name called) or securities in connection with any loan(s) (or other form of debt) given directly or indirectly by the listed entity to promoter(s), promoter group, director(s) (including their relatives), key managerial personnel (including their relatives) or any entity controlled by them are in the economic interest of the company.		Yes	Textual Information(3)
Name	DARSHIT SHAH		
Designation	CFO		
Place	AHMEDABAD		
Date	20-04-2022		

Signatory Details	
Name of signatory	MAHENDRA G. PATEL
Designation of person	Managing Director
Place	AHMEDABAD
Date	20-04-2022

